Development of a highly specific and sensitive VHH-based sandwich immunoassay for the detection of the SARS-CoV-2 nucleoprotein
暂无分享,去创建一个
N. Escriou | B. Raynal | J. D. Di Santo | X. Montagutelli | S. Brier | M. Prot | J. Bellalou | S. Brûlé | S. Petres | P. Lafaye | Gabriel Aymé | P. England | F. Lazarini | F. Déjardin | P. Gonçalves | F. Donati | Marion Gransagne | Gaëlle Chauveau-Le Friec | Véronique Mériaux | M. Nowakowski | S. Levallois | Guilherme Dias de Melo | Sébastien Brûlé
[1] E. Goldman,et al. Single-Domain Antibodies for the Detection of SARS-CoV-2 Nucleocapsid Protein , 2021, Analytical chemistry.
[2] T. Cokelaer,et al. COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters , 2021, Science Translational Medicine.
[3] J. Jaubert,et al. The B1.351 and P.1 variants extend SARS-CoV-2 host range to mice , 2021, bioRxiv.
[4] A. Sigal,et al. Sixteen novel lineages of SARS-CoV-2 in South Africa , 2021, Nature Medicine.
[5] M. Biggerstaff,et al. Emergence of SARS-CoV-2 B.1.1.7 Lineage — United States, December 29, 2020–January 12, 2021 , 2021, MMWR. Morbidity and mortality weekly report.
[6] Jonathan L. Schmid-Burgk,et al. COVID-19 Bibliometrics 8 th – 14 th February 2021 , 2021 .
[7] G. Leung,et al. Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020 , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[8] D. Schneidman-Duhovny,et al. Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2 , 2020, Science.
[9] G. Gao,et al. Structures of the SARS‐CoV‐2 nucleocapsid and their perspectives for drug design , 2020, The EMBO journal.
[10] T. Gibson,et al. Ultra-sensitive Serial Profiling of SARS-CoV-2 Antigens and Antibodies in Plasma to Understand Disease Progression in COVID-19 Patients with Severe Disease , 2020, Clinical chemistry.
[11] Y. Yazdanpanah,et al. A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations , 2020, Science Translational Medicine.
[12] D. Brody,et al. High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme , 2020, Scientific Reports.
[13] R. Owens,et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2 , 2020, Nature Structural & Molecular Biology.
[14] Lisa E. Gralinski,et al. SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract , 2020, Cell.
[15] K. Nadeau,et al. A highly sensitive bioluminescent method for measuring allergen‐specific IgE in microliter samples , 2020, Allergy.
[16] Jiajia Xie,et al. Biochemical characterization of SARS-CoV-2 nucleocapsid protein , 2020, Biochemical and Biophysical Research Communications.
[17] Q. Jin,et al. Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain , 2020, Nature Communications.
[18] Evzen Boura,et al. Structural basis of RNA recognition by the SARS-CoV-2 nucleocapsid phosphoprotein , 2020, bioRxiv.
[19] N. Callewaert,et al. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies , 2020, Cell.
[20] Xavier Duval,et al. Clinical and virological data of the first cases of COVID-19 in Europe: a case series , 2020, The Lancet Infectious Diseases.
[21] Fabian J Theis,et al. SARS-CoV-2 Entry Genes Are Most Highly Expressed in Nasal Goblet and Ciliated Cells within Human Airways , 2020, Nature Medicine.
[22] Zhicong Yang,et al. The SARS-CoV-2 outbreak: What we know , 2020, International Journal of Infectious Diseases.
[23] Lei Liu,et al. A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients , 2020, Microbes and Infection.
[24] Jie Zheng,et al. Recommendations for performing, interpreting and reporting hydrogen deuterium exchange mass spectrometry (HDX-MS) experiments , 2019, Nature Methods.
[25] Jinquan Luo,et al. Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin , 2018, Science.
[26] P. Lafaye,et al. Use of camel single-domain antibodies for the diagnosis and treatment of zoonotic diseases , 2018, Comparative Immunology, Microbiology and Infectious Diseases.
[27] Ulrich Rothbauer,et al. Under the Microscope: Single-Domain Antibodies for Live-Cell Imaging and Super-Resolution Microscopy , 2017, Front. Immunol..
[28] C. Duyckaerts,et al. Camelid single-domain antibodies: A versatile tool for in vivo imaging of extracellular and intracellular brain targets. , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[29] Stevenn Volant,et al. MEMHDX: an interactive tool to expedite the statistical validation and visualization of large HDX-MS datasets , 2016, Bioinform..
[30] D. Falzarano,et al. SARS and MERS: recent insights into emerging coronaviruses , 2016, Nature Reviews Microbiology.
[31] G. Gao,et al. Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses , 2016, Trends in Microbiology.
[32] François Ferron,et al. Structural characterization of the N‐terminal part of the MERS‐CoV nucleocapsid by X‐ray diffraction and small‐angle X‐ray scattering , 2016, Acta crystallographica. Section D, Structural biology.
[33] B. Raynal,et al. Quality assessment and optimization of purified protein samples: why and how? , 2014, Microbial Cell Factories.
[34] H. Ploegh,et al. Intracellular Expression of Camelid Single-Domain Antibodies Specific for Influenza Virus Nucleoprotein Uncovers Distinct Features of Its Nuclear Localization , 2014, Journal of Virology.
[35] Alastair D G Lawson,et al. Functional inhibition of β-catenin-mediatedWnt signaling by intracellular VHHantibodies , 2014, mAbs.
[36] B. Fielding,et al. The Coronavirus Nucleocapsid Is a Multifunctional Protein , 2014, Viruses.
[37] J. Vandekerckhove,et al. Stratifying fascin and cortactin function in invadopodium formation using inhibitory nanobodies and targeted subcellular delocalization , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[38] A. Meola,et al. An alpaca nanobody inhibits hepatitis C virus entry and cell‐to‐cell transmission , 2013, Hepatology.
[39] J. Bourgeois,et al. Cell‐penetrating anti‐GFAP VHH and corresponding fluorescent fusion protein VHH‐GFP spontaneously cross the blood‐brain barrier and specifically recognize astrocytes: application to brain imaging , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[40] R. Weiss,et al. Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization , 2012, The Journal of experimental medicine.
[41] B. Schepens,et al. Nanobodies®: new ammunition to battle viruses. , 2011, Antiviral research.
[42] R. Weiss,et al. Llama-Derived Single Domain Antibodies to Build Multivalent, Superpotent and Broadened Neutralizing Anti-Viral Molecules , 2011, PloS one.
[43] Chi Zhang,et al. Pre-expression of a sulfhydryl oxidase significantly increases the yields of eukaryotic disulfide bond containing proteins expressed in the cytoplasm of E.coli , 2011, Microbial cell factories.
[44] S. Muyldermans,et al. In vitro antiviral activity of single domain antibody fragments against poliovirus. , 2010, Antiviral research.
[45] Charles Duyckaerts,et al. Llama VHH antibody fragments against GFAP: better diffusion in fixed tissues than classical monoclonal antibodies , 2009, Acta Neuropathologica.
[46] C. Duyckaerts,et al. Single-domain antibodies recognize selectively small oligomeric forms of amyloid beta, prevent Abeta-induced neurotoxicity and inhibit fibril formation. , 2009, Molecular immunology.
[47] R. Weiss,et al. Llama Antibody Fragments with Cross-Subtype Human Immunodeficiency Virus Type 1 (HIV-1)-Neutralizing Properties and High Affinity for HIV-1 gp120 , 2008, Journal of Virology.
[48] P. Güntert,et al. Solution Structure of the C-terminal Dimerization Domain of SARS Coronavirus Nucleocapsid Protein Solved by the SAIL-NMR Method , 2007, Journal of Molecular Biology.
[49] H. de Haard,et al. Properties, production, and applications of camelid single-domain antibody fragments , 2007, Applied Microbiology and Biotechnology.
[50] C. Hsiao,et al. Structure of the SARS Coronavirus Nucleocapsid Protein RNA-binding Dimerization Domain Suggests a Mechanism for Helical Packaging of Viral RNA , 2007, Journal of Molecular Biology.
[51] Raymond C. Stevens,et al. Ribonucleocapsid Formation of Severe Acute Respiratory Syndrome Coronavirus through Molecular Action of the N-Terminal Domain of N Protein , 2007, Journal of Virology.
[52] Lennart Hammarstrom,et al. Reduction in morbidity of rotavirus induced diarrhoea in mice by yeast produced monovalent llama-derived antibody fragments. , 2006, Vaccine.
[53] V. Chow,et al. The Nucleocapsid Protein of Severe Acute Respiratory Syndrome-Coronavirus Inhibits the Activity of Cyclin-Cyclin-dependent Kinase Complex and Blocks S Phase Progression in Mammalian Cells , 2006, Journal of Biological Chemistry.
[54] I. Yu,et al. Recombinant Severe Acute Respiratory Syndrome (SARS) Coronavirus Nucleocapsid Protein Forms a Dimer through Its C-terminal Domain , 2005, Journal of Biological Chemistry.
[55] P. Schuck,et al. Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling. , 2000, Biophysical journal.
[56] S. Muyldermans,et al. Naturally occurring antibodies devoid of light chains , 1993, Nature.